Étiquette : cancer

Cannabinoids, Endocannabinoids and Cancer, Daniel J. Hermanson and Lawrence J. Marnett , 2011

Cannabinoids, Endocannabinoids and Cancer Daniel J. Hermanson and Lawrence J. Marnett Cancer Metastasis Reviews, 2011, 30, (3-4), 599–612. doi:10.1007/s10555-011-9318-8.   1. Introduction 1.1 Cannabinoid Function Endocannabinoids are bioactive lipids that have a range of interesting activities mediated by two G-protein-coupled receptors (CB1 and CB2) and other putative targets [1-3]. The CB1 receptor is present in the central nervous system and mediates the psychotropic effects of exogenous cannabinoids such as Δ9-tetrahydrocannabinol (THC), the active component of marijuana. In the brain, endocannabinoids and cannabinoids combine with CB1 cannabinoid receptors on axon terminals and regulate ion channel activity and neurotransmitter release [4]. Binding to the CB1 receptor is responsible for [...]

Lire la suite

Opportunities for cannabis in supportive care in cancer, Amber S. Kleckner et al., 2019

Opportunities for cannabis in supportive care in cancer Amber S. Kleckner , Ian R. Kleckner, Charles S. Kamen, Mohamedtaki A. Tejani, Michelle C. Janelsins, Gary R. Morrow and Luke J. Peppone Therapeutic Advances in Medical Oncology, 2019, Vol. 11, 1–29 DOI: 10.1177/1758835919866362   Abstract Cannabis has the potential to modulate some of the most common and debilitating symptoms of cancer and its treatments, including nausea and vomiting, loss of appetite, and pain. However, the dearth of scientific evidence for the effectiveness of cannabis in treating these symptoms in patients with cancer poses a challenge to clinicians in discussing this option with their patients. A review was [...]

Lire la suite

Priority Considerations for Medicinal Cannabis-Related Research, Marcel O. Bonn-Miller et al.,

Priority Considerations for Medicinal Cannabis-Related Research Marcel O. Bonn-Miller, Charles V. Pollack, Jr., David Casarett, Richard Dart, Mahmoud ElSohly, Larry Good, Manuel Guzman, Lumır Hanus, Kevin P. Hill, Marilyn A. Huestis, Eric Marsh, Susan Sisley, Nancy Skinner, Judith Spahr, Ryan Vandrey, Eugene Viscusi, Mark A. Ware, and Donald Abrams Cannabis and Cannabinoid Research, 2019, Volume 4, Number 3, 1-19. DOI: 10.1089/can.2019.0045   Keywords : medicinal cannabis; medical marijuana   Introduction and Rationale The National Academy of Sciences, Engineering, and Medicine’s 2017 publication The Health Effects of Cannabis and Cannabinoids: The Current State of Evidence and Recommendations for Research provided a significant contribution by synthesizing the existing evidence base [...]

Lire la suite

Flavonoid Derivative of Cannabis Demonstrates Therapeutic Potential in Preclinical Models of Metastatic Pancreatic Cancer, Michele Moreau et al., 2019

Flavonoid Derivative of Cannabis Demonstrates Therapeutic Potential in Preclinical Models of Metastatic Pancreatic Cancer Michele Moreau, Udoka Ibeh, Kaylie Decosmo Noella Bih, Sayeda Yasmin-Karim, Ngeh Toyang, Henry Lowe5 and Wilfred Ngwa Frontiers in Oncology, July 2019, Vol. 9, article 660. doi: 10.3389/fonc.2019.00660   Abstract Pancreatic cancer is particularly refractory to modern therapies, with a 5-year survival rate for patients at a dismal 8%. One of the significant barriers to effective treatment is the immunosuppressive pancreatic tumor microenvironment and development of resistance to treatment. New treatment options to increase both the survival and quality of life of patients are urgently needed. This study reports on a new [...]

Lire la suite

Pilot Study of Psilocybin Treatment for Anxiety in Patients With Advanced-Stage Cancer, Charles S. Grob et al., 2010

Pilot Study of Psilocybin Treatment for Anxiety in Patients With Advanced-Stage Cancer Charles S. Grob,  Alicia L. Danforth,  Gurpreet S. Chopra,  Marycie Hagerty, Charles R. McKay, Adam L. Halberstadt,  George R. Greer Archive of  General Psychiatry, 2010, 68, (1), 71–78 doi: 10.1001/archgenpsychiatry.2010.116   Context : Researchers conducted extensive investigations of hallucinogens in the 1950s and 1960s. By the early 1970s, however, political and cultural pressures forced the cessation of all projects. This investigation reexamines a potentially promising clinical application of hallucinogens in the treatment of anxiety reactive to advanced-stage cancer. Objective : To explore the safety and efficacy of psilocybin in patients with advanced-stage cancer and [...]

Lire la suite

Serotonergic hallucinogens in the treatment of anxiety and depression in patients suffering from a life-threatening disease : A systematic review, Simon Reiche et al., 2018

Serotonergic hallucinogens in the treatment of anxiety and depression in patients suffering from a life-threatening disease : A systematic review Simon Reiche, Leo Hermle, Stefan Gutwinskic Henrik Jungaberle, Peter Gasser, Tomislav Majić Progress in Neuropsychopharmacology & Biological Psychiatry, 2018, 81, 1–10 http://dx.doi.org/10.1016/j.pnpbp.2017.09.012   A B S T R A C T Anxiety and depression are some of the most common psychiatric symptoms of patients suffering with lifethreatening diseases, often associated with a low quality of life and a poor overall prognosis. 5-HT2A-receptor agonists (serotonergic hallucinogens, ‘psychedelics’) like lysergic acid diethylamide (LSD) and psilocybin were first investigated as therapeutic agents in the 1960s. Recently, after a long [...]

Lire la suite

Medical Marijuana Use in Oncology : A Review, Gianna Wilkie et al., 2016

Medical Marijuana Use in Oncology : A Review Gianna Wilkie,  Bachir Sakr, Tina Rizack JAMA Oncology, 2016, 2, (5), 670-675. doi:10.1001/jamaoncol.2016.0155   IMPORTANCE : Medicinal marijuana use is currently legal in 23 states and the District of Columbia. As more states approve marijuana use for medical indications, physicians will be asked by their patients for more information regarding the risks and benefits of use. This article reviews the history, adverse effects, and proposed mechanisms of action of marijuana and summarizes the available literature regarding symptom relief and therapeutic value in patients with cancer. OBSERVATIONS : Marijuana in oncologymay have potential for use as an antiemetic, for [...]

Lire la suite

Psilocybin Scientific Papers, AEDMP, 2014

Psilocybin Scientific Papers AEDMP  - Asociación para el Estudio y la Divulgación de la Medicina Psicodélica Research conducted by: Fco. Miguel Ríos & Genís Oña  - 2014 - Asociación para el Estudio y la Divulgación de la Medicina Psicodélica. Castellarnau, 11 2º 1ª 43004 Tarragona Spain Tel. 675 55 33 44 Email: medicina.psicodelica@hotmail.com www.medicinapsicodelica.org   Content _____________________________________ 1.   What is Psilocybin? 2.   Scientific papers about Psilocybin arranged chronologically (1959-2014) -   A. Hofmann (1959). Chemical Aspects of Psilocybin, the Psychotropic Principle from the Mexican Fungus,  Psilocybe Mexicana  Heim  -   S. Malitz et al. (1960). Some Observations on Psilocybin, a New Hallucinogen, in Volunteer Subjects  -   L. E. [...]

Lire la suite

Psychedelics in the treatment of unipolar mood disorders : a systematic review, James J.H. Rucker et al., 2016

Psychedelics in the treatment of unipolar mood disorders : a systematic review James J.H. Rucker, Luke A. Jelen, Sarah Flynn, Kyle D. Frowde and Allan H. Young Journal of Psychopharmacology, 2016, 1-10 DOI: 10.1177/0269881116679368 Abstract Unipolar mood disorders, including major depressive disorder and persistent depressive disorder (dysthymia), confer high rates of disability and mortality and a very high socioeconomic burden. Current treatment is suboptimal in most cases and there is little of note in the pharmaceutical development pipeline. The psychedelic drugs, including lysergic acid diethylamide and psilocybin, were used extensively in the treatment of mood disorders, and other psychiatric conditions, before their prohibition in the [...]

Lire la suite

Potential Therapeutic Effects of Psilocybin, Matthew W. Johnson & Roland R. Griffiths, 2017

Potential Therapeutic Effects of Psilocybin Matthew W. Johnson & Roland R. Griffiths Neurotherapeutics, 2017, 14, 734–740 DOI 10.1007/s13311-017-0542-y Abstract Psilocybin and other 5-hydroxytryptamine2A agonist classic psychedelics have been used for centuries as sacraments within indigenous cultures. In the mid-twentieth century they were a focus within psychiatry as both probes of brain function and experimental therapeutics. By the late 1960s and early 1970s these scientific inquires fell out of favor because classic psychedelics were being used outside of medical research and in association with the emerging counter culture. However, in the twenty-first century, scientific interest in classic psychedelics has returned and grown as a result of [...]

Lire la suite